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Abstract
Background: Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper
cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular
endothelial growth factor monoclonal antibody used in association with chemotherapy in metastatic colorectal cancer.
Some studies have previously shown that IL-17A and IL-17F polymorphisms, respectively rs2275913 and rs763780, are
associated with gastric or colorectal cancer risk. Here we aimed at studying the influence of IL-17A-related individual
factors on overall survival and progression-free survival in patients with metastatic colorectal cancer treated with
a bevacizumab-based chemotherapy.
Methods: Pre-treatment serum biomarkers were retrospectively evaluated in 122 metastatic colorectal cancer
patients treated by bevacizumab in combination with chemotherapy at 2-weeks intervals in a prospective cohort study
(NCT00489697). The polymorphisms of IL-17A and IL-17F were analyzed by polymerase chain reaction - restriction
fragment length polymorphism. Serum concentrations of Th17-related cytokines were measured by MultiPlex. The
impact of individual parameters on overall survival and progression-free survival was assessed using multivariate
Cox models.
Results: High baseline IL-17A serum concentrations were significantly associated with shorter progression-free
survival [p = 0.043]. Other baseline serum Th17-related cytokines and polymorphisms of IL-17 were not associated
with overall survival or progression-free survival.
Conclusions: In this ancillary study, baseline serum IL-17A concentration is the only Th17/IL-17 related factor that
was significantly associated with the response of patients with metastatic colorectal cancer to bevacizumab. But
this main significant result is highly dependent on one case which, if left out, weakens the data. Other clinical
studies are required to confirm this association.
Trial registration: NCT00489697. June 20, 2007.
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Background
Colorectal cancer is a major public health issue due to its
frequency and its severity [1]. It is a major cause of death
in the world [2]. The therapeutic arsenal against meta-
static colorectal cancer was strengthened by the addition
of monoclonal antibodies to chemotherapy. Bevacizumab
(Avastin® [3]) is a humanized IgG1 that binds to the
vascular endothelial growth factor (VEGF), a well known
pro-angiogenic growth factor [4] which favors tumors and
metastasis. Bevacizumab is widely used in the treatment
of patients with advanced colorectal cancer [5].
Though bevacizumab prolongs survival of patients with
metastatic colorectal cancer, some individuals do not
respond to treatment [6] and it is difficult to identify at an
early stage who will benefit or not from this biopharma-
ceutical. Our team has recently showed that antigenic
burden influences bevacizumab pharmacokinetics in
patients with metastatic colorectal cancer [7]. In this
study, bevacizumab pharmacokinetics was also influenced
by baseline VEGF and CarcinoEmbryonic Antigen (CEA)
concentrations and by the number of extra-hepatic metas-
tases. These differences in bevacizumab pharmacokinetics
between patients are relevant since bevacizumab con-
centrations are associated with progression-free (PFS)
and overall survival (OS) of patients [7]. There is however
a need to identify other early biomarkers that could be
predictive of response to anti-VEGF biopharmaceuticals.
Several studies suggest that interleukin-17 (IL-17A or
IL-17 or cytotoxic T-lymphocyte-associated protein 8)
plays a major role in colorectal cancer progression [8–12]
and in the resistance to anti-VEGF treatment in murine
models [13] or chemotherapy [14, 15]. IL-17A is a pro-
inflammatory cytokine that contributes to the pathogenesis
of inflammatory and auto-immune diseases [16, 17] but
that also seems to be highly associated with cancer pro-
gression [18, 19]. A major source of IL-17 is a lineage of T
cells known as CD4+ T helper 17 cells (Th17 cells) which
differ from the Th1 and Th2 subsets [20]. IL-17 is also
secreted by other cell types of the immune system including
lymphocytes NKT-17, γδT-17, CD8+ Tc17, poly-
morphonuclear neutrophils and intestinal Paneth cells
[21, 22]. IL-17 homodimers signal through the complex
formed by heterodimer IL-17 Receptor (R)A/IL-17RC.
Interleukin-17 F (IL-17F) is a recently described member
of the IL-17 family with a great homology to IL-17A.
IL-17F is mainly secreted by T CD4+ and γδT-17 lym-
phocytes and acts as homodimers or heterodimers with
IL-17A [23]. It signals through the same receptors as
IL-17A, with a better affinity to IL-17RC. However, its
role and function in inflammation and cancer, a priori
close to those of IL-17A, need to be further investi-
gated. In colon cancer, these two cytokines could have
in fact opposite effects since IL-17A favors cancer de-
velopment and IL-17F appears to be a protective factor
against tumorigenesis [18, 24]. Notably, IL-17A polymor-
phisms were associated with increased risk of colorectal
cancer development when comparing patients to healthy
controls in Iranian and Tunisian populations [25, 26].
Interestingly IL-17F polymorphisms was observed to be
mainly protective in the same populations [25, 27].
To our knowledge, there is no data concerning serum
Th17-related cytokines concentration or Il-17-related
polymorphisms that may be predictive of the clinical
impact of bevacizumab in metastatic colorectal cancer
or be at least implicated in the prognosis of the disease,
in this particular treatment schedule. The objective of
the present study was therefore to evaluate the association
of individual sources of variability related to IL-17 pathway
with OS and PFS of patients with metastatic colorectal
cancer treated with a bevacizumab-based regimen. In
addition to biomarkers previously assessed, i.e. CEA,
VEGF and bevacizumab concentrations [7], we studied
the influence of baseline serum Th17-related cytokines
concentrations (before bevacizumab treatment initi-
ation) and of selected IL-17A (G197A, rs2275913) and




This ancillary study is part of a French multicenter
non-comparative, prospective, open-label, observational
study (NCT00489697, registration first received June 20,
2007). The study is also registered as ID number INCA06-
FT/STIC-AVASTIN. The main study was designed to evalu-
ate the usefulness of hepatic contrast-enhanced ultrasound
sonography as predictor of response to bevacizumab-based
chemotherapy in patients with metastatic colorectal
cancer. Briefly, patients enrolled between January 2007
and December 2010 received 5 mg/kg bevacizumab
intravenously with two-week intervals in combination
with chemotherapy. Tumor response was assessed by
RECIST criteria (response evaluation criteria in solid
tumors [28]) using spiral Computed Tomography (CT)
before treatment and at day 60 after the beginning of
the treatment. The end of follow-up was December
2012. Finally, 122 patients received at least the four
bevacizumab infusions.
This study was designed in accordance with legal
requirements and the Declaration of Helsinki and was
approved by the ethics committee of Tours University
Hospital, France. All patients gave written informed
consent to participate in this study, including constitu-
tional genetic analyses. Eligible patients (18–80 years old)
had histologically confirmed metastatic colorectal cancer
with at least one hepatic metastasis detected by ultrason-
ography, a life expectancy of more than two months, a
World Health Organization performance status of two or
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less and were mostly treated as first line treatment with a
bevacizumab-based chemotherapy.
Polymerase chain reaction-restriction fragment length
polymorphism (PCR-RFLP)
Genomic DNA was extracted from peripheral blood
leukocytes. Patients were genotyped using specific primers.
100 ng/μl DNA was amplified with Taq Polymerase solu-
tion (Life Technologies, Saint-Aubin, France), including
MgCl2 (2.5 mM) and dNTP (5 nM). PCR reactions were
performed in 35 cycles of denaturation at 95 °C for 5 s and
primer annealing and extension at 60 °C for 45 s.
IL-17A rs2275913 (G197A) sequence was amplified with
the following primers previously validated by Wu et al. [29]:
Forward 5′-AAC AAG TAA GAA TGA AAA GAG
GAC ATG GT-3′.
Reverse 5′-CCC CCA ATG AGG TCA TAG AAG
AAT C-3′.
Il-17F rs763780 (A7488G) was amplified with the fol-
lowing primers previously validated by Wrobel et al. [30]:
Forward 5′-ACC AAG GCT GCT CTG TTT CT-3′.
Reverse 5′-GGT AAG GAG TGG CAT TTC TA-3′.
PCR products were digested overnight at 37 °C with
FastDigest XagI (EcoNI, Fermentas, Illkirch, France) for
rs2275913 variant and with FastDigest NlaIII (Hin1II,
Fermentas) for rs763780 variant. The fragments were
then separated on 8% TBE polyacrylamide gels (Invitrogen)
and visualized after staining with ethidium bromide under
UV light. The visualized DNA products for rs2275913 were
102 bp (AA genotype), 102 + 68 + 34 bp (AG genotype)
and 68 + 34 bp (GG genotype). The visualized products for
rs763780 were 412 bp (GG genotype), 412 + 288 + 124 bp
(AG genotype) and 288 + 124 bp (AA genotype).
Multiplex
Baseline concentrations of Th17-related cytokines were
measured in serum samples using multiplex assay fol-
lowing manufacturer’s protocol (Bio-Plex Pro™ Human
Th17 Cytokine Assays, Bio-Rad, Marnes-la-Coquette,
France). This magnetic bead–based immunoassay allows
to measure 15 proteins involved in the Th17 immune
response pathway: IL-1β, IL-4, IL-6, IL-10, IL-17A,
IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFNγ,
TNF-α and sCD40L.
Survival analysis
Overall survival (OS) was defined as the time from first
bevacizumab infusion to death from any cause, and
progression-free survival (PFS) was defined as the time
from first bevacizumab infusion to documented disease
progression. OS and PFS were assessed using Cox semi-
parametric (univariate and multivariate) proportional
hazard regression models. This analysis aimed at testing
and quantifying the association of circulating Th17-related
cytokines concentrations (IL-1β, IL-4, IL-6, IL-10, IL-17A,
IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFNγ, TNF-
α and sCD40L) and gene polymorphisms (IL-17A, GG vs
AA + AG carriers; IL-17F, AA vs AG) as covariates of Cox
models. The association between these covariates and OS
or PFS, was assessed using forward and backward stepwise
procedures. The relationship between survival and the
following variables was also examined: age at inclusion,
gender, bevacizumab trough concentrations before the sec-
ond injection (Ctrough; <15.5 mg/L (median) vs ≥15.5 mg/L),
and baseline concentrations of VEGF and CEA. For inter-
leukin concentration measurements, values below the limit
of detection (LOD) were replaced by the LOD value. Hazard
ratios (HR) and their corresponding 95% confidence
intervals (95% CI) were estimated. The association between
covariates and survival functions was tested using Wald’s
test, with alpha risk (p) <0.05. Cox survival analyses were
performed using R Software version 3.2.2 (The R Foundation
for Statistical Computing, Vienna, Austria).
Results
Demographic data and clinical features (Table 1)
One hundred and thirty patients were included but we
analyzed only the 122 patients who received at least the
four bevacizumab infusions. Median age was 65 years
and patients were predominantly men (77%). The major-
ity of patients were diagnosed for a colon cancer (72%),
surgically resected (63%) with hepatic metastases only
(58%). Bevacizumab associated with FOLFIRI was mostly
used as first-line treatment (66%). The Table 1 below
sums up the demographic data of patients and baseline
measures (notably CEA, VEGF and bevacizumab con-
centrations), previously assessed [7].
Polymorphisms
For rs2275913 IL-17A polymorphism, genotypes were
distributed as follows (Table 2): homozygous AA 10.9%,
heterozygous AG 51.1% and homozygous GG 38%. For
rs763780 IL-17F polymorphism, genotypes were distrib-
uted as follows (Table 2): homozygous AA 92.6% and
homozygous AG 7.4%. There were no homozygous GG
for this polymorphism in our study.
There was no association between the genotypes and
serum cytokine levels in this cohort.
Cytokine concentrations
The concentrations of cytokines involved in the Th17
immune response pathway are summarized in Table 3.
IFNγ was detected in none of the included patients. The
distribution of IL-17A concentrations was shown in Fig. 1
since it was the only Th17-related cytokine associated
with PFS (see below the detailed Cox multivariate analysis,
Table 5). For this cytokine, the range of values was similar
to previous studies [11, 31].
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There was no association between chemotherapy back-
bone and outcomes or Th17-related cytokines levels in
this cohort.
Overall survival (Table 4)
Median OS was 23.9 months (95% CI, 20.6–31.3 months).
The univariate Cox analysis identified high baseline VEGF,
IL-31 and CEA concentrations, and low bevacizumab
Ctrough as risk factors of death. In the multivariate analysis,
high baseline CEA concentrations (HR = 1.15; 95% CI,
1.04–1.27; P = 0.0064) and low bevacizumab Ctrough
(<15.5 mg/L; HR = 1.89; 95% CI, 1.20–2.97; P = 0.0063)
were independent risk factors of death.
Table 2 Distribution and frequencies of IL-17A and IL-17F










Table 3 Baseline concentrations of serum Th17-related cytokines
(n = 122)
















Fig. 1 Distribution of baseline serum IL-17A concentrations of patients
with metastatic colorectal cancer
Table 1 Demographic data of patients and baseline measures
(n = 122)
Baseline patients’ characteristics (n = 122)
Age, years 65 [58–72]
Weight, kg 68 [60–77]
Height, cm (n = 121) 170 [163–174]
Body surface area, m2 (n = 121) 1.75 [1.64–1.93]
Carcinoembryonic antigen, μg/L (n = 111) 68.6 [11.8–271.3]]
Vascular endothelial growth factor,
ng/L (n = 119)
169.6 [61.9–334.5]
Ctrough bevacizumab, mg/L 15.5 [11.7–22.8]
Time to progression, months 10.6 [7.4–16.1]
Follow-up period, months 23.9 [14.7–35.3]
Gender male 77 (63%)
female 45 (37%)
World Health Organization Performance




Primary tumor site Colon 85 (70%)
Rectal 37 (30%)




Results are expressed as median [interquartile range] for continuous variables
or number (%) for categorical variables.
Abbreviations: n number of patients, FOLFIRI oxaliplatin, 5-fluorouracil, and
leucovorin, FOLFOX irinotecan, 5-fluorouracil, and leucovorin, LV5FU2 leucovorin
and 5-fluorouracil
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Progression-free survival (Table 5)
Median PFS was 10.6 months (95% CI, 9.6–12.4 months).
The univariate analysis showed that high baseline IL-17A,
VEGF and CEA concentrations, and low bevacizumab
Ctrough were risk factors of progression. In the multi-
variate analysis, high baseline concentrations of IL-17A
(HR = 1.02; 95% CI, 1.00–1.04; P = 0.043) and VEGF
(HR = 2.34; 95% CI, 1.31–4.20; P = 0.0041), and low
bevacizumab Ctrough ((<15.5 mg/L; HR = 1.72; 95% CI,
1.17–2.53; P = 0.0059) were independent risk factors of
progression. In this new set of analysis and considering
the selected Th17/IL-17A-related factors, VEGF and
bevacizumab concentrations remain independent risks
factors as recently described by Caulet et al. [7].
We next assessed whether the combination of the
independent factors identified by multivariate Cox analysis
would increase the predictive ability of each individual
factor for PFS. A risk score was calculated for each patient,
by summing-up the number of high-risk factors defined as
IL-17A and VEGF concentrations above the respective
median values, and bevacizumab Ctrough below the median.
Median PFS was significantly longer in patients with <2
high-risk factors compared to those with ≥2 high-risk
factors (12.9 vs 8.7 months, P = 0.0006 by log-rank
test; Fig. 2).
Discussion
Drugs that target the VEGF pathway, associated with
chemotherapy backbone, have a significant impact in
metastatic colorectal cancer therapy . Bevacizumab in
combination with chemotherapy has been proven to
extend OS in first-line therapy [5] and in second-line
therapy [32]. A pooled analysis from seven phase II and
III (3763 patients) demonstrated that the use of bevacizumab
with chemotherapy was associated with statistically
significant benefits in survival outcomes, compared to
chemotherapy alone, in the treatment of metastatic
colorectal cancer [33].
According to the literature, IL-17A is involved in colorec-
tal cancer progression, in cancer resistance and tumor es-
cape following anti-VEGF-based therapy [11, 13, 15, 18, 34].
In addition, IL-17A is a factor that regulates T cell plasticity
Table 4 Cox regression analyses of potential factors associated
with overall survival in patients with metastatic colorectal cancer
(n = 122)
HR 95% CI p
Univariate analysis: Covariate
Gender (female) 0.68 0.44–1.06 0.092
Age, years 1.01 0.99–1.03 0.55
Vascular endothelial growth factor, μg/L 2.09 1.10–3.99 0.025
Ctrough bevacizumab <15.5 mg/L 2.34 1.52–3.58 9.9 × 10
−5
Log(carcinoembryonic antigen), μg/L 1.21 1.10–1.34 9.8 × 10−5
IL17A polymorphism (A carriers) 0.86 0.56–1.30 0.47
IL17F polymorphism (AG) 1.80 0.87–3.73 0.11
IL-1β, pg/mL 1.23 0.69–2.21 0.48
IL-4, pg/mL 1.00 0.99–1.01 0.96
IL-6, pg/mL 1.00 0.99–1.00 0.49
IL-10, pg/mL 1.00 0.99–1.02 0.61
IL-17A, pg/mL 1.01 0.99–1.03 0.22
IL-17F, pg/mL 0.99 0.97–1.01 0.34
IL-22, pg/mL 1.07 0.99–1.15 0.057
IL-31, pg/mL 1.00 1.00–1.004 0.019
IL-33, pg/mL 1.00 0.99–1.00 0.95
sCD40L, pg/mL 1.00 0.86–1.06 0.83
Tumor necrosis factorα, pg/mL 0.97 0.86–1.09 0.61
Multivariate analysis: Covariate
Ctrough bevacizumab <15.5 mg/L 1.88 1.19–2.97 0.0064
Log(CEA), μg/L 1.15 1.04–1.28 0.0057
Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, Ctrough trough
concentration of bevacizumab before second infusion
Table 5 Cox regression analyses of potential factors associated
with progression-free survival in patients with metastatic colorectal
cancer (n = 122)
HR 95% CI p
Univariate analysis: Covariate
Gender (female) 0.70 0.47–1.03 0.07
Age, years 1.01 0.99–1.02 0.52
Vascular endothelial growth factor, μg/L 2.54 1.44–4.48 0.0013
Ctrough bevacizumab <15.5 mg/L 1.88 1.28–2.74 0.0011
Log(carcinoembryonic antigen), μg/L 1.10 1.02–1.19 0.017
IL-17A polymorphism (A carriers) 0.80 0.55–1.17 0.26
IL-17F polymorphism (AG) 1.27 0.64–2.52 0.49
IL-1β, pg/mL 1.34 0.77–2.33 0.31
IL-4, pg/mL 1.00 0.99–1.01 0.74
IL-6, pg/mL 1.00 0.59–0.55 0.55
IL-10, pg/mL 1.01 0.99–1.02 0.49
IL-17A, pg/mL 1.02 1.00–1.04 0.026
IL-17F, pg/mL 1.00 0.99–1.02 0.65
IL-22, pg/mL 1.03 0.95–1.10 0.49
IL-31, pg/mL 1.00 0.99–1.00 0.089
IL-33, pg/mL 1.00 0.99–1.00 0.13
sCD40L, pg/mL 1.00 0.99–1.00 0.8
Tumor necrosis factorα, pg/mL 1.10 0.99–1.21 0.067
Multivariate analysis: Covariate
Vascular endothelial growth factor, μg/L 2.34 1.31–4.20 0.0041
Ctrough bevacizumab <15.5 mg/L 1.72 1.17–2.53 0.0059
IL-17A, pg/mL 1.02 1.001–1.04 0.043
Abbreviations: HR hazard ratio, 95% CI 95% confidence interval, Ctrough trough
concentration of bevacizumab before second infusion
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and might also promote antitumor immunity [35]. In
syngeneic tumor pre-clinical models, Chung et al. [13]
well described how IL-17A is implicated in a network
that favors tumor escape following anti-VEGF treatment,
notably via an IL17/G-CSF (granulocyte colony-stimulating
factor)/Bv8 (prokineticin-2) alternative pathway initiated by
Th17 infiltration. To study the relevancy of their pre-
clinical findings, they investigated notably tissue sec-
tions from patients with colorectal cancer. Aa strong
correlation of IL-17A–positive lymphocytes and Bv8-
expressing polymorphonuclear granulocytes was found.
In our ancillary study, we therefore sought to investi-
gate the influence of IL-17A-related individual factors
on OS and PFS in patients with metastatic colorectal
cancer treated with bevacizumab mainly associated
with FOLFIRI regimen.
In addition to the risk factors of progression reported by
Caulet et al. [7] and regarding this cohort of patients with
advanced colorectal cancer treated with a bevacizumab-
based regimen, serum IL-17A baseline concentrations
were identified as an independent factor and no influence
of other Th17/Il-17A-related markers was observed.
To our knowledge, this is the first report that investigates
IL-17A and its related factors as potential biomarkers of
response of bevacizumab-based regimen in advanced colo-
rectal cancer. However this study has some limitations
since there is no control arm without bevacizumab therapy,
which means that our findings have a prognostic role and
other studies are needed to validate a predictive value.
We can not conclude on whether our finding is attributable
to bevacizumab alone or in combination with backbone
chemotherapy. A recent systematic meta-analysis showed
that there was no statistically significant difference in effi-
cacy when bevacizumab is used with both irinotecan- or
oxaliplatin-based regimens [36].
Some reports indicated that IL-17A could initiate and
favour the tumoral progression at early colorectal cancer
stages [8, 37] so it could be interesting to evaluate the
impact of IL-17A concentrations at this time in future
prospective studies including bevacizumab treatment.
Wang et al. measured IL-17A concentrations in serum
of patients with colorectal cancer that did not receive
bevacizumab infusions [31]. They showed that significantly
higher IL-17A concentrations were found at early colorectal
cancer stages (I/II) concomitantly with increased concen-
trations of Il-23, another interleukin linked to Th17 differ-
entiation, compared to control healthy donors. Tseng et al.
also found that high IL-17A concentrations at stage II were
associated with shorter disease-free survival in an in-
dependent analysis [11]. Moreover, retrospectively and
irrespective of bevacizumab therapy, Tosolini et al. [38]
showed that colorectal cancer patients with high expres-
sion of the Th17 genes cluster, analyzed from frozen speci-
mens, had a poor prognosis and this result was confirmed
with the quantification of IL-17-positive cells in situ. To
date, only one team reported that high IL-17A expression,
compared to expression in adenoma and non-tumor
tissue, is an independent favorable prognostic factor
that predicts overall survival of colorectal cancer by
quantifying RNA expression in tissues and IL-17A
immunohistochemical levels [39]. All the other publi-
cations reported that IL-17A high expression (RNA,
immunohistochemistry and/or serum concentration) is
a negative prognostic marker of colorectal cancer pro-
gression [8, 9, 38, 40].
The rs2275913 polymorphism can promote production
of high levels of IL-17A and lead to enhanced IL-17-
mediated immune responses. The rs763780 polymorph-
ism leads to a Histidine-to-Arginine substitution and
therefore antagonizes the function of wild-type IL-17F
[41]. In our study we observed no influence of IL-17A
and IL-17F polymorphisms on OS and PFS of our
bevacizumab-treated group of patients with metastatic
colorectal cancer.
Among individual Th17-related potential biomarkers,
only baseline serum IL-17A concentrations are herein
associated with PFS in patients with metastatic colorectal
cancer treated with a bevacizumab-based chemotherapy.
We can extrapolate that the clinical response could be
influenced by or associated with other individual Th17-
related biomarkers in larger panels or at early stages of the
disease, e.g. IL-6 and IL-23 as markers of Th17 maturation
or IL-17 and TNF-α as the main secreted factors. The fact
that Il-17A was the only significant Th17-related factor
associated with PFS must be reproducibly analyzed in
other prospective studies. Moreover, it is important to
distinguish the impact of IL-17A and the infiltration of
Th17 cells. A recent meta-analysis following Prisma guide-
lines emphasizes the fact that high IL-17A quantities were
Fig. 2 Kaplan–Meier plots. Progression-free survival according to the
score calculated by baseline concentrations of plasma VEGF and
serum IL-17A and bevacizumab Ctrough. P = 0.0006 by log-rank test
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correlated with poor prognosis in cancer and notably
in colorectal cancer but the impact of high Th17 cell
frequencies is very controversial and depends on the
cancer type [42].
Conclusions
To conclude, we think that evaluation of serum IL-17A
concentration alone is probably not clinically relevant
and IL-17A concentration should be assessed as an
additional risk factor, along with baseline VEGF con-
centration and bevacizumab Ctrough. It could help to
stratify patients with metastatic colorectal cancer receiving
bevacizumab as first-line treatment according to their risk
of disease progression (see Fig. 2). Considering the range of
hazard ratios and p values in the Cox regression multivari-
ate analysis, serum Il-17A concentrations play a significant
role in the risk score but to a lesser degree than plasma
VEGF and bevacizumab trough concentrations. But this
significant result is highly dependent on one case which, if
left out, weakens the data. Therefore the association should
be confirmed in other clinical studies. And the determin-
ation of IL-17A concentrations at baseline, along with base-
line VEGF concentrations and bevacizumab Ctrough, could
also be embedded in the design strategy for future
prospective clinical trials. In a near future, it would be
interesting to target IL-17A, concomitantly or sequentially
to VEGF inhibition, to overcome resistance to anti-VEGF-
based therapy in metastatic colorectal cancer.
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